STOCK TITAN

AtriCure to Participate in the 22nd Annual Needham Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

AtriCure, a leader in innovative surgical treatments for atrial fibrillation (Afib), announced its participation in the 22nd Annual Needham Virtual Healthcare Conference. The company’s management will conduct a fireside chat on April 17, 2023, at 1:30 PM EST. Interested parties can access a live audio webcast in the ‘Investors’ section on AtriCure's website. AtriCure focuses on the development of technologies for Afib treatment and LAA management, with over 37 million individuals affected by Afib globally. The firm’s devices, including the Isolator® Synergy™ Ablation System and the AtriClip® LAA Exclusion System, are widely used by healthcare professionals.

Positive
  • None.
Negative
  • None.

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 22nd Annual Needham Virtual Healthcare Conference.

AtriCure’s management is scheduled to participate in a fireside chat on Monday, April 17, 2023 at 1:30 pm Eastern Standard Time. Interested parties may access a live audio webcast by visiting the “Investors” section of the company’s website at https://ir.atricure.com.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

Angie Wirick

AtriCure, Inc.

Chief Financial Officer

(513) 755-5334

awirick@atricure.com

Lynn Lewis or Marissa Bych

Gilmartin Group

Investor Relations

lynn@gilmartinir.com

marissa@gilmartinir.com

Source: AtriCure, Inc.

FAQ

When is AtriCure's presentation at the Needham Virtual Healthcare Conference?

AtriCure's management is scheduled to participate in a fireside chat on April 17, 2023, at 1:30 PM EST.

How can I access the AtriCure conference presentation?

You can access the live audio webcast by visiting the 'Investors' section of AtriCure's website.

What is AtriCure known for?

AtriCure is recognized for its innovative technologies for treating atrial fibrillation and managing left atrial appendage complications.

What are some key products offered by AtriCure?

Key products include the Isolator® Synergy™ Ablation System and the AtriClip® Left Atrial Appendage Exclusion System.

How many people are affected by atrial fibrillation worldwide?

Atrial fibrillation affects more than 37 million people globally.

AtriCure, Inc.

NASDAQ:ATRC

ATRC Rankings

ATRC Latest News

ATRC Stock Data

1.48B
47.21M
3.18%
105.58%
3.43%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
MASON